Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-12-31 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-09-30 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-12-31 was -800.49K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-09-30 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 25.00K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 88.94K shares, a 80.18% decline from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2014 was 448.69K shares, a 19.65% increase from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2013 was 375.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | 25.00K shares 10-K · filed 2019-03-07 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | |
| 2015-12-31 | -800.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | 88.94K shares 10-K · filed 2018-03-09 |
| 2015-09-30 | 0.00 shares 10-Q · filed 2015-11-02 | 889.43K shares derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-06-30 | 7.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 889.43K shares derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-03-31 | 881.93K shares 10-Q · filed 2015-05-08 | 1.24M shares derived: sum of 4 quarters · filed 2017-02-24 |
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | 448.69K shares 10-K · filed 2017-02-24 |
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-02 | 448.69K shares derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | 361.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 823.69K shares derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | 87.50K shares 10-Q · filed 2015-05-08 | 462.50K shares derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 375.00K shares 10-K · filed 2016-03-14 |
| 2013-09-30 | 375.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | 375.00K shares derived: sum of 4 quarters · filed 2014-11-12 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | 0.00 shares derived: sum of 4 quarters · filed 2013-08-12 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-09 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | 0.00 shares 10-K · filed 2013-03-22 |
| 2012-09-30 | 0.00 shares 10-Q · filed 2012-11-08 | |
| 2011-12-31 | 80.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | 183.00K shares 10-K · filed 2013-03-22 |
| 2011-09-30 | 28.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |